The Pulmonary Complications of Paraneoplastic Autoimmune Vasculitis in a Patient With Myelodysplastic Syndrome.

alveolar hemorrhage mds myelodysplastic syndrome paraneoplastic vasculitis

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
19 Jul 2020
Historique:
entrez: 22 8 2020
pubmed: 22 8 2020
medline: 22 8 2020
Statut: epublish

Résumé

Paraneoplastic autoimmune phenomena may occur in up to 30% of patients with myelodysplastic syndrome (MDS). We present the case of a patient with MDS who developed diffuse alveolar hemorrhage due to paraneoplastic autoimmune vasculitis. The patient was a 55-year-old male who had been referred for outpatient hematology/oncology evaluation by his primary care physician for incidentally discovered thrombocytopenia. When he presented to the clinic, he reported new-onset chills, weakness, and night sweats. He endorsed a 20-pound weight loss over two months as well as two weeks of fatigue, exertional dyspnea, and epistaxis. He was noted to be ill-appearing and had bilateral pitting edema to the knees. Vital signs revealed a temperature of 102.3 °F, oxygen saturation of 84% on room air, and tachycardia to the 90s. Labs showed hemoglobin of 5.7 g/dL, hematocrit of 17.2 g/dL, and platelet count of 27 kµL. He was admitted to the hospital for blood and platelet transfusions, empiric antibiotics, and further diagnostic studies. The peripheral blood smear showed 4% blasts and frequent dyspoietic granulocytes. Bone marrow biopsy (BMB) was performed to differentiate between acute leukemia and myelodysplasia. BMB revealed myelodysplasia with excess blasts and erythroid predominance.During hospitalization, the patient developed acute hypoxemic respiratory failure due to bronchoscopy-confirmed diffuse alveolar hemorrhage from thrombocytopenia. His platelet count was 12 kµL. High-dose corticosteroids (2 mg/kg prednisone) were initiated for suspected paraneoplastic autoimmune vasculitis, pending BMB results. The patient steadily improved, was extubated, and had reduced oxygen and transfusion requirements.High-dose steroids were stopped, and the patient was started on decitabine chemotherapy with the ultimate goal of bone marrow transplantation. On day five of decitabine, the patient developed acute hypoxic respiratory failure requiring intubation as well as hypotension requiring vasopressors. Given that recurrent diffuse alveolar hemorrhage was again suspected, high-dose steroids were resumed upon transfer to the ICU. He continued to decompensate and ultimately experienced ventricular tachycardia requiring three separate episodes of cardiopulmonary resuscitation. Per the family's wishes, he was palliatively extubated, and he expired an hour later. Diffuse alveolar hemorrhage is a rare but potentially deadly pulmonary complication of MDS, stemming from a paraneoplastic autoimmune vasculitis. Patients who initially present with atypical autoimmune phenomena should raise suspicion for an underlying MDS, the presence of which can guide the promptness, extent, and duration of immunosuppressive therapy. Failure to expeditiously treat these patients with corticosteroids can lead to serious complications and death.

Identifiants

pubmed: 32821625
doi: 10.7759/cureus.9282
pmc: PMC7431304
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e9282

Informations de copyright

Copyright © 2020, Jagadish et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Blood. 2013 Oct 24;122(17):2943-64
pubmed: 23980065
Blood Res. 2016 Dec;51(4):217-219
pubmed: 28090480
Medicine (Baltimore). 2014 Jan;93(1):1-10
pubmed: 24378738
J Transl Int Med. 2017 Sep 30;5(3):139-143
pubmed: 29085786
Arthritis Rheum. 2007 Dec 15;57(8):1473-80
pubmed: 18050165
Br J Haematol. 2014 Feb;164(4):503-25
pubmed: 24372298
Gan To Kagaku Ryoho. 2010 Jun;37(6):980-3
pubmed: 20567097
Hematol Rep. 2016 May 10;8(2):6480
pubmed: 27499837
Br J Haematol. 1995 Oct;91(2):403-8
pubmed: 8547082
Blood. 2011 Oct 13;118(15):4041-52
pubmed: 21828139
Expert Rev Clin Immunol. 2014 Dec;10(12):1679-88
pubmed: 25308147

Auteurs

Pooja S Jagadish (PS)

Internal Medicine, The University of Tennessee Health Science Center, Memphis, USA.

Anna-Carson R Uhelski (AR)

Medicine, Johns Hopkins Hospital, Baltimore, USA.
Medicine, The University of Tennessee Health Science Center, Memphis, USA.

Jordan Redfield (J)

Internal Medicine, The University of Tennessee Health Science Center, Memphis, USA.

Nicholas Thomson (N)

Hematology and Oncology, The University of Tennessee Health Science Center, Memphis, USA.

Osarenren Ogbeide (O)

Internal Medicine/Hematology/Oncology, Veterans Affairs Hospital, Memphis, USA.

Classifications MeSH